PRAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Praxis Precision Medicines Inc (PRAX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong analyst support with multiple price target increases, significant growth potential in its CNS product pipeline, and upcoming catalysts such as earnings and conference presentations. While the financials show negative revenue, the company's focus on transformative treatments and its FDA Breakthrough Therapy Designation for ulixacaltamide provide a strong growth narrative.
The stock is showing bullish momentum with moving averages (SMA_5 > SMA_20 > SMA_200) and a pre-market price increase of 0.39%. However, the MACD histogram is negative (-0.13), indicating potential short-term consolidation. RSI is neutral at 77.439, and the stock is trading near its resistance level (R1: 331.409).
Multiple analyst upgrades with significantly increased price targets and strong buy ratings.
FDA Breakthrough Therapy Designation for ulixacaltamide, with a high probability of approval (80%-90%).
Upcoming earnings report and conference presentations, which could provide further positive momentum.
Strong growth potential in the CNS market, with peak sales estimates exceeding $20B.
Financials show no revenue and negative net income, though losses have narrowed YoY.
Wells Fargo's cautious outlook on ulixacaltamide approval, assigning a 50% probability of success.
No significant trading trends from hedge funds or insiders, indicating neutral sentiment.
In Q3 2025, the company reported a 100% YoY revenue decline to $0, while net income improved by 42.43% YoY to -$73.93M. EPS also improved by 22.18% YoY to -3.36. Gross margin dropped to 0%, reflecting the company's pre-revenue stage as it focuses on R&D and clinical trials.
Analyst sentiment is overwhelmingly positive, with multiple firms raising price targets significantly (e.g., H.C. Wainwright to $1,245, Piper Sandler to $1,200, Guggenheim to $800). Analysts cite strong growth potential for ulixacaltamide and relutrigine, with peak sales estimates exceeding $20B and a high probability of FDA approval for key products. The stock is considered a top pick for 2026 by several firms.
